DR SIMON TSO (Orcid ID : 0000-0001-9221-7618)
DR HASEEB MOIZ (Orcid ID : 0000-0001-9037-1427)

Article type : Review Article

Erythroderma (exfoliative dermatitis) part one: underlying causes, clinical presentation and pathogenesis

S. Tso,1 F. Satchwell,1 H. Moiz,2 H. Tushar,3 S. Dhariwal,1 R. Barlow,4 E. Forbat,4 H. Randeva,8,9 Y.T. Tan,7 A. Ilchyshyn,4 M. Kwok,5 T.M. Barber,8,9 C. Thind1 and A. Tso6

1 Jephson Dermatology Centre, South Warwickshire NHS Foundation Trust, Warwick, CV34 5BW, United Kingdom.
2 University of Warwick, Coventry, CV4 7AL, United Kingdom.
3 University of Buckingham Medical School, Buckingham, MK18 1EG, United Kingdom.
4 Department of Dermatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, United Kingdom
5 Anaesthetics, Westmead Hospital, New South Wales, Australia
6 Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore.
7 Department of Cardiology, South Warwickshire NHS Foundation Trust, Warwick, CV34 5BW, United Kingdom
8 Warwick Medical School, University of Warwick, CV4 7AL, United Kingdom
9 Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, United Kingdom

Corresponding author: Dr Simon Tso
Email: simontso@doctors.org.uk.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/CED.14625

This article is protected by copyright. All rights reserved
Abstract

Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1 to 2 persons per 100,000 population in Europe with a higher male-to-female ratio. Erythroderma may present at birth, develop acutely or insidiously (due to progression of an underlying primary pathology, including malignancy). Whilst there is a broad range of diseases that associate with erythroderma, the vast majority of cases result from pre-existing and chronic dermatoses. In part one of this two part concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.

Introduction

Erythroderma (exfoliative dermatitis) represents a dermatological emergency, and presents with extensive erythematous skin and scaling, affecting ≥90% of body surface area. First described by Von Hebra in 1868, erythroderma represents a cutaneous inflammatory state, with associated dysfunction of both the skin barrier and metabolic processes. Many diseases associate with erythroderma. Most cases result from pre-existing and chronic dermatoses. In part one of this
concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.

**Underlying causes of erythroderma**

Erythroderma manifests from severe skin dysmetabolism, reported in severe forms of a range of diseases that could be broadly categorised into congenital, infective, inflammatory, immunobullous, neoplastic, iatrogenic and idiopathic causes. Table 1 shows the range of diseases associated with the clinical presentation of erythroderma, including key clinical features and reading references. Commonly, erythroderma results from exacerbations of pre-existing dermatoses, such as psoriasis or eczema. Psoriatic erythroderma may result from sudden withdrawal of systemic or very potent topical corticosteroids. Drug-related erythroderma eruptions are often caused by anticonvulsants, antibiotics and topical preparations. A detailed chronological history, including clinical improvement upon drug cessation, are essential for the determination of the causative drug, which can often prove challenging. Table 2 shows the distribution of the various causes of erythroderma. Despite our knowledge and understanding of the many and varied causes of erythroderma, the precise cause may not be established in up to one in six cases.

**Clinical presentation of erythroderma**

Erythroderma may present at birth, and develops either acutely (e.g. due to infection or drugs), or more gradually due to the progression of an underlying primary pathology, including dermatoses and malignancies. Associated signs and symptoms may give further clues to the underlying aetiology of erythroderma.

Congenital erythroderma may co-present with a diversity of cutaneous and extra-cutaneous clinical features at birth and later on in life. In the case of autosomal recessive congenital ichthyosis, affected infants may co-present with collodion membrane, ectropion, eclabium and folded ears at birth, which may be further complicated by hair and nail abnormalities, hypohidrosis and skin contractures in the case of Harlequin Ichthyosis. In Netherton syndrome, the skin have the characteristic ‘double edged’ ichthyosis linearis circumflexa appearance; the hair shaft is abnormal and brittle (trichorrhexis invaginata) and affected children have a predisposition to atopy. Developmental delays in children born with congenital erythroderma should always prompt
the screening of syndromic forms of congenital ichthyosis and neutral lipid storage disease (e.g. Chanarin-Dorfman syndrome). In erythroderma due to primary acrodermatitis enteropathica, the presentation of perioral and perianal dermatitis may not present until after affected infants begin to wean off breast milk. Congenital erythroderma may also co-present in severe combined immunodeficiency, a rare disease associated with alopecia, chronic diarrhoea, failure to thrive, lymphadenopathy and hepatosplenomegaly.

Acute erythroderma usually manifests clinically as widespread erythema, followed by exfoliative scaling over the subsequent 2-6 days. The morphology of the rash preceding erythroderma varies significantly according to the underlying cause and particular attention to co-presenting symptoms is required to aid in diagnosis of the underlying cause. Viral exanthems typically presents as an acute morbilliform macular and/or maculopapular eruption spreading in a cephalocaudal direction. Drug eruptions may begin as a morbilliform or urticarial rash, which can further develop pustules at flexural sites (in acute generalised exanthematous pustulosis), lymphadenopathy (in drug reaction with eosinophilia and systemic symptoms) or mucocutaneous skin erosions and blistering (in Stevens-Johnson syndrome and toxic epidermal necrolysis). Patients presenting with erythrodermic psoriasis may co-present with severe nail dystrophy. Erythroderma due to underlying immunobullous disease may present with intact and de-roofed mucocutaneous blisters or erosions. Erythroderma in the context of unexplained weight loss, lymphadenopathy and presence of atypical lymphocytes (in blood film) in absence of pre-existing skin diseases should prompt consideration of underlying malignancies such as Sézary syndrome.

Thermoregulatory disturbances (fever and chills), reactive lymphadenopathy and superimposed bacterial infections may occur concurrently with erythroderma from all causes. In extreme cases, sequelae of erythroderma include hypovolaemia (with reflex tachycardia), high-output cardiac failure, anaemia, electrolyte disturbances, and acute respiratory distress syndrome.

Pathogenesis of erythroderma

*Congenital erythroderma:* Disorders of lipid metabolism underpin the pathogenesis of a range of differential causes of congenital erythroderma. Reviews by Elias et al (2008) and Radner et al (2013) extensively discuss the pathogenesis of genodermatoses secondary to abnormalities and
dysregulation in fatty acid metabolism, cholesterol metabolism, triglyceride metabolism and lipid transportation. In brief, disordered lipid metabolism leads to abnormal lipid organisation within the stratum corneum, therefore, interfering with normal lateral packing of lipids, which is crucial for the barrier function of the skin. This abnormality has been observed in lamellar ichthyosis and atopic dermatitis.

Acquired erythroderma: The pathogenesis of acquired erythroderma is poorly understood. Studies suggested that factors such as an increase in serum immunoglobulin E, interleukin-4 and interleukin-10 associated with Th1/Th2 imbalance in favour of Th2 differentiation and dysregulated angiogenic factors could have a role in the pathogenesis of erythrodermic psoriasis. Interleukin-4 and interleukin-13 signalling are central to the pathogenesis of atopic dermatitis and other atopic diseases through activation of downstream IgE dependent processes that leads to activation of mast cells and eosinophils and the clinical presentation of skin inflammation. Indeed, dermal eosinophilic infiltrates is a characteristic histological feature observed in skin biopsies from patients with erythrodermic atopic dermatitis and this finding may also be observed in allergic contact dermatitis, urticaria, immunobullous diseases and dermal hypersensitivity reaction patterns. Interleukin-4 and interleukin-13 are targets for blockade by dupilumab, a licensed biologic treatment for moderate to severe atopic dermatitis.

The pathogenesis of erythroderma in patients with haematological malignancies is poorly understood and the changes to cytokine signalling profile in this group of patients is highly complex. Nevertheless, there is an increase in the Th2 profile of cytokines such as interleukin-4, interleukin-5 and interleukin-10 in the skin and serum of patients with Sézary syndrome; overexpression of interleukin-13 signalling in cutaneous T-cell lymphoma; and upregulation of interleukin-4 signalling in the bone marrow in patients with acute myeloid leukemia. The link between interleukin-4 and interleukin-13 signalling in the pathogenesis of erythroderma in patients with haematological malignancies remains speculative given the lack of relevant studies.

Regardless of the underlying cause of erythroderma, there is an increase in expression of adhesion molecules (increased VCAM-1, ICAM-1, E-selectin and P-selectin expression found on endothelium in-situ in patients with erythroderma, mycosis fungoides and atopic dermatitis) and
pro-inflammatory mediators stimulating dermal inflammation and epidermal turnover rate, which shortens the keratinocyte transit time through the epidermis, resulting in exfoliation.¹

**Discussion**

Our literature review identifies that globally, the most common cause of erythroderma is due to an underlying primary skin disease. However, to the best of our knowledge there is no recent UK data about the differential causes of erythroderma². Therefore, advancement of our current clinical management of erythroderma is reliant upon developing our knowledge of the underlying pathogenesis in order to identify possible targets for therapeutic intervention. Identification of specific raised molecular cytokines may allow us to subtype erythroderma cases and manage accordingly. The pathogenesis of erythroderma remains unclear but the interleukin-4 and interleukin-13 pathways appear to be an attractive potential treatment target for managing erythroderma with unclear cause.

**Conclusion**

A wide range of diseases can lead to erythroderma but its pathogenesis remains poorly understood.

**Learning Points**

- Infants presenting with erythroderma at birth or within the first year of life should always prompt the consideration of inherited metabolic diseases.
- Pre-existing dermatoses (particularly psoriasis and eczema) underlie a significant proportion of cases of erythroderma, as shown in the current literature to date.
- Regarding the acute presentation of erythroderma, the morphological nature of the rash preceding erythroderma and co-presenting symptoms are of great significance to aid in aetiological diagnosis.
- In erythrodermic psoriasis, studies have suggested factors such as increased serum immunoglobulin E, interleukin-4 and interleukin-10 associated with favoured Th2 differentiation and dysregulated angiogenic factors could have a role in the pathogenesis.
References

1. Okoduwa C, Lambert WC, Schwartz RA, Kubeyinje E, Eitokpah A, Sinha S, Chen W. Erythroderma: review of a potentially life-threatening dermatosis. Indian journal of dermatology. 2009 Jan;54(1):1.

2. Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep. 2020;10(1):9774. doi: 10.1038/s41598-020-66040-7.

3. Harper-Kirksey K. Erythroderma. InLife-Threatening Rashes 2018 (pp. 265-277). Springer, Cham.

4. Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care. 2015; 28(5):228-36; quiz 237-8. doi: 10.1097/01.ASW.0000463573.40637.73.

5. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res. 2008 Apr; 49(4): 697–714. doi: 10.1194/jlr.R800002-JLR200.

6. Radner FPW, Marrakchi S, Kirchmeier P, Kim GJ, Ribierre F, Kamoun B, Abid L, Leipoldt M, Turki H, Schempp W, Heilig R, Lathrop M, Fischer J. Mutations in CERS3 Cause Autosomal Recessive Congenital Ichthyosis in Humans. PLoS Genet. 2013; 9(6): e1003536. doi: 10.1371/journal.pgen.1003536.

7. Groen D, Poole DS, Gooris GS, Bouwstra JA. Is an orthorhombic lateral packing and a proper lamellar organization important for the skin barrier function? Biochim Biophys Acta. 2011 Jun;1808(6):1529-37. doi: 10.1016/j.bbamem.2010.10.015.

This article is protected by copyright. All rights reserved.
8. Pilgram GS, Vissers DC, van der Meulen H, Pavel S, Lavrijsen SP, Bouwstra JA, Koerten HK. Aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis. J Invest Dermatol. 2001 Sep;117(3):710-7. doi: 10.1046/j.0022-202x.2001.01455.x.

9. Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Liao W. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93-104. doi: 10.2147/PTT.S101232. Epub 2016 Jul 20.

10. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017 May;13(5):425-437. doi: 10.1080/1744666X.2017.1298443. Epub 2017 Mar 15. PMID: 28277826.

11. Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM. Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. JAMA Dermatol. 2015 Jul;151(7):753-60. doi: 10.1001/jamadermatol.2015.2. PMID: 25760640

12. Fung MA. The clinical and histopathologic spectrum of "dermal hypersensitivity reactions," a nonspecific histologic diagnosis that is not very useful in clinical practice, and the concept of a "dermal hypersensitivity reaction pattern". J Am Acad Dermatol. 2002 Dec;47(6):898-907.

13. Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sézary syndrome expresses a Th2-type profile. J Invest Dermatol. 1994 Jul;103(1):29-33. doi: 10.1111/1523-1747.ep12388985.

14. Geskin LJ, Viragova S, Stolz DB, Fuschietti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015 Apr 30;125(18):2798-805. doi: 10.1182/blood-2014-07-590398. Epub 2015 Jan 27. PMID: 25628470; PMCID: PMC4424628.

15. Gao A, Gong Y, Zhu C, Yang W, Li Q, Zhao M, Ma S, Li J, Hao S, Cheng H, Cheng T. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019 Oct;104(10):1950-1961. doi: 10.3324/haematol.2018.214593. Epub 2019 Feb 21. PMID: 30792200; PMCID: PMC6886411.
16. Sigurdsson V, de Vries IJ, Toonstra J, Bihari IC, Thepen T, Bruijnzeel-Koomen CA, van Vloten WA. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol. 2000 Oct;27(9):436-40. doi: 10.1034/j.1600-0560.2000.027009436.x. PMID: 11028813.

17. Hoeger PH, Harper JI, Neonatal erythroderma: differential diagnosis and management of the “red baby” Archives of Disease in Childhood 1998;79:186-191.

18. Dhar S, Banerjee R, Malakar R. Neonatal erythroderma: diagnostic and therapeutic challenges. Indian J Dermatol. 2012; 57(6):475-478.

19. Nacim Louhichi, Emna Bahloul, Slaheddine Marrakchi, Houda Ben Othman, Chahnez Triki, Kawthar Aloulou, Lobna Trabelsi, Nadia Mahfouth, Zeineb Ayadi-Mnif, Leila Keskes, Faiza Fakhfakh & Hamida Turki Thyroid involvement in Chanarin-Dorfman syndrome in adults in the largest series of patients carrying the same founder mutation in ABHD5 gene. Orphanet Journal of Rare Diseases volume 14, Article number: 112 (2019)

20. Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005 May 9;5:5.

21. Mathew R, Sreedevan V. Erythroderma: A clinicopathological study of 370 cases from a tertiary care center in Kerala. Indian J Dermatol Venereol Leprol. 2017 Sep-Oct;83(5):625. doi: 10.4103/0378-6323.198434. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2017;volume=83;issue=5;spage=625;epage=625;aulast=Mathew

22. Scrivener Y, Cribier B, Le Coz C, Boehm N, Jelen G, Heid E, Grosshans E. Erythrodermic Psoriasis and HIV Infection. N Engl J Med. 2019 Jan 3;380(1):80. doi: 10.1056/NEJMcm1810005. PMID: 30601728.

23. Bowles AA, Smirnov B. Erythrodermic Psoriasis and HIV Infection. N Engl J Med. 2019 Jan 3;380(1):80. doi: 10.1056/NEJMcm1810005. PMID: 30601728.

24. Paparizos V, Vasalou V, Velissariou E, Kourkounti S, Daskalakis E, Rigopoulos D. Norwegian scabies presenting as erythroderma in HIV: A case report. Infez Med. 2019 Sep 1;27(3):332-335. PMID: 31545779.
25. Lim PN, Fox CP, Pammi M, Patel A. Paraneoplastic erythroderma: unusual presentation secondary to diffuse large B cell lymphoma. BMJ Case Reports 2019;12:e228412.
26. Leenutaphong V, Kulthanan K, Pohboon C, Suthipinittharn P, Sivayathorn A, Sunthonpalin P. Erythroderma in Thai patients. J Med Assoc Thai. 1999 Aug;82(8):743-8.
27. Sudho R, Hussain SB, Bellraj E, Frederick M, Mahalaxmi V, Sobhana S, Anandan S. Clinicopathological study of exfoliative dermatitis. Indian J Dermatol Venereol Leprol. 2003 Jan-Feb;69(1):30-1.
28. Yuan XY, Guo JY, Dang YP, Qiao L, Liu W. Erythroderma: A clinical-etiological study of 82 cases. Eur J Dermatol. 2010 May-Jun;20(3):373-7. doi: 10.1684/ejd.2010.0943. Epub 2010 Apr 19. PMID: 20400388.
29. Rym BM, Mourad M, Bechir Z, Dalenda E, Faika C, Iadh AM, Amel BO. Erythroderma in adults: a report of 80 cases. Int J Dermatol. 2005 Sep;44(9):731-5. doi: 10.1111/j.1365-4632.2004.02100.x. PMID: 16135140.
30. Pal, MCPS, FCPS, S. and Haroon, FRCP, FCPS, T.S. (1998), Erythroderma: a clinico-etioologic study of 90 cases. International Journal of Dermatology, 37: 104-107. doi:10.1046/j.1365-4362.1998.00228.x

Table 1. Diseases associated with erythroderma and useful diagnostic features.
Table 2. Literature review of the differential causes of erythroderma from different geographical locations worldwide.
| Category          | Examples                                                                 | Useful diagnostic features and investigations                                                                 | Useful references to read |
|------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------|
| Congenital       | Ichthyosis and keratinopathies                                            | Clinical History:                                                                                              | Hoeger and Harper, 1998<sup>17</sup> |
|                  | • Syndromic forms without skin blisters such as:                          | Starts at birth. Inherited forms of acrodermatitis enteropathica may commence after the infant weans.          | Dhar et al, 2012<sup>18</sup> |
|                  |   - Netherton syndrome (AR),                                               |                                                                                                               | Nacim et al, 2019<sup>19</sup> |
|                  |   - Sjögren-Larsson syndrome (AR)                                          |                                                                                                               |                           |
|                  |   - Dorfman-Chanarin syndrome (AR)                                         |                                                                                                               |                           |
|                  |   - Refsum syndrome (AR),                                                  |                                                                                                               |                           |
|                  |   - Keratitis-ichthyosis-deafness (KID) syndrome (AR)                      |                                                                                                               |                           |
|                  |   - Conradi-Hünermann-Happle syndrome (XLD)                                |                                                                                                               |                           |
|                  |   - Congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD) syndrome (XLD) |                                                                                                               |                           |
|                  |   - Ichthyosis follicularis, atrichia and photophobia (IFAP) syndrome     |                                                                                                               |                           |
|                  | Clinical signs:                                                            | Collodion membrane may be present at birth in syndromic and non-syndromic forms of congenital ichthyosis.     |                           |
|                  |   - Recessive X-linked ichthyosis only affects males and typically presents with generalised scale within 6 months of birth, and may co-present with undescended testicles and corneal opacities. |                                                                                                               |                           |
|                  | Investigations:                                                            |                                                                                                               |                           |
|                  |   - Relevant gene panels.                                                   |                                                                                                               |                           |
|                  |   - Serum immunoglobulin level in Omenn syndrome.                          |                                                                                                               |                           |
|                  |   - Serum zinc level in inherited forms of acrodermatitis                 |                                                                                                               |                           |
| (XLR and AD) | enteropathica. |
|-------------|----------------|
| X-linked ichthyosis (XLR) | |
| • Non-syndromic forms such as: | |
| - Lamellar ichthyosis (AR) | |
| - Non-bullous congenital ichthyosiform erythrokerma (AR) | |
| - Harlequin ichthyosis (AR) | |
| • Non-syndromic forms with blistering such as: | |
| - Epidermolytic ichthyosis (AD and AR) | |

**Immunodeficiency syndromes**
- Omenn syndrome (AR)
- Hyper IgE syndrome

**Metabolic disorders**
- Holocarboxylase synthetase deficiency (AR)
- Inherited form of acrodermatitis enteropathica (AR)
| Inflammatory | Eczema | Psoriasis | Pityriasis rubra pilaris (PRP) | Seborrhoeic dermatitis | Clinical History: | Clinical signs: | Investigations: | PRP typically presents with palmoplantar keratoderma. | Palmoplantar keratoderma in PRP. | Nail pitting and dystrophy in psoriasis. | Full blood count (especially eosinophil count) and skin biopsy. | HIV screening in severe seborrheic dermatitis. | Atopic dermatitis: total immunoglobulin E level | Akhyani et al, 2005<sup>20</sup> | Mathew et al, 2017<sup>21</sup> |
|--------------|--------|-----------|-------------------------------|------------------------|-------------------|----------------|----------------|-------------------------------------------------|-------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Immuno-bullous | Subcorneal | - Pemphigus foliaceus (PF) | - Pemphigus vulgaris (PV) | Clinical History: | BP may presents with a pre-bullous stage with widespread urticated pruritic plaques before blistering commence. History of | | | | | | | | Scrivener et al, 1998<sup>22</sup> |
| Sub-epidermal | **Bullous pemphigoid** (BP) | oral and genital ulceration is a key history in PV. Patients may not report any blisters in PV and PF. |
|--------------|-----------------------------|--------------------------------------------------------------------------------------------------|

**Clinical signs:**
Scale, crust, erosion, typically confined to the skin in PF but sparing the mucosa.
Urticated plaques, larger intact and deroofed bullae in BP.
In PV, mucosal erosions and ulceration is a key feature and may or may not affect the skin.

**Investigations:**
Skin histology: BP shows subepidermal blistering; PF and PV shows intraepidermal blistering.
Skin direct immunofluorescence microscopy (IMF): PV and PF shows intercellular surface staining pattern; BP shows linear basement membrane zone pattern.
ELISA: key features are desmoglein 1 in PF; desmoglein 3 in PV; BP180 and BP230 in BP.
| Infective | Human immunodeficiency virus (HIV) | Clinical History and signs: | Mathew et al, 2017<sup>21</sup> |
|-----------|----------------------------------|-----------------------------|--------------------------|
|           | Scabies                          | HIV- opportunistic and recurrent infections | Bowles et al, 2019<sup>23</sup> |
|           | Staphylococcus scalded skin syndrome (SSSS) | Scabies- widespread pruritis and erythematous rash with burrows on dermoscopy. SSSS- fever, malaise and widespread fluid-filled blistering rash. | Paparizos et al, 2019<sup>24</sup> |
|           |                                  | Investigations:              |                          |
|           |                                  | HIV- CD4 count and HIV viral load. |                          |
|           |                                  | Scabies – dermoscopy to identify burrows; skin biopsy to identify mites. |                          |
|           |                                  | SSSS - skin biopsy (intraepidermal cleavage at granular layer), microbiology skin swabs and blood culture |                          |

| Neoplastic | Cutaneous T-cell lymphoma | Clinical History and signs: | Lim et al, 2018<sup>25</sup> |
|------------|--------------------------|-----------------------------|--------------------------|
|            | B cell lymphoma          | Unexplained weight loss, lymphadenopathy, pruritus |                          |
|            | Paraneoplastic pemphigus | Investigations:             |                          |
|            | Malignancies, especially, haematological and solid organ | Blood test screening |                          |
|            |                          | Flow cytometry              |                          |
|            |                          | Skin biopsy                 |                          |
|            |                          | Lymph node/ Bone marrow biopsy |                          |
| Immune | Hypersensitivity | Immunodeficiency | Autoimmune |
|--------|-----------------|-----------------|------------|
|        | Contact dermatitis | Graft-versus-host disease (GvHD) | Systemic lupus erythematosus (SLE) |
|        | Erythroderma multiforme major (EM-major) |                |            |
|        | Steven-Johnson syndrome (90% cases) |                |            |

Clinical History and signs:

EM-major: about 90% cases caused by infections (especially Herpes virus) and 10% caused by drugs; presenting as target like erythematous lesions and polymorphous rash.

SJS: 90% cases associated with infections and typically presents with mucocutaneous skin erosions and conjunctivitis.

History of allogenic transplant in GvHD. Acute GvHD occurs within 3 months of transplantation and may be associated with gastrointestinal and liver dysfunction. Chronic GvHD may associate with dry eyes, scleroderma, hair loss, nail dystrophy, liver, lung and gastrointestinal dysfunction.

Extra-cutaneous features in SLE can include arthritis, pleurisy, pericarditis, kidney disease, neuropathy, etc.

Investigations:
Blood test screening –
| autoantibodies.  
Skin biopsy. Patch testing in contact dermatitis. |
| Condition                                      | Clinical History:                                                                 | Clinical signs:                                                                 | Investigations:                                                                                     |
|-----------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Erythoderma multiforme major (10% cases)       | May present with systemic symptoms such as malaise, fever                         | Lymphadenopathy and hepatosplenomegaly may present in DRESS syndrome.           | Blood test screening for eosinophilia and deranged liver function test. Skin biopsy.                 |
| Drug reaction with eosinophilia and systemic symptoms (DRESS) |                                                                              | Pustular lesions developing at flexural sites may suggest AGEP or bacterial skin infection. |                                                                                                    |
| Steven-Johnson Syndrome (10% cases)           |                                                                              |                                                                                                   |                                                                                                    |
| Toxic epidermal necrolysis                     |                                                                              |                                                                                                   |                                                                                                    |
| Acute generalised exanthematous pustulosis (AGEP) |                                                                              |                                                                                                   |                                                                                                    |
| Acrodermatitis enteropathica (inherited or acquired) |                                                                              | Triad of psoriasiform dermatitis of circumoral or periorificial areas, alopecia and diarrhoea. | Blood test screening for nutritional deficiencies.                                                 |
### Table 1. Diseases associated with erythroderma and useful diagnostic features.

| Others       | Cutaneous mastocytosis | Hypereosinophilic syndrome | Sunburn                              |
|--------------|-------------------------|---------------------------|--------------------------------------|
|              | Clinical history and sign: Mastocytosis: rubbing an area of affected skin can activate mast cells leading to skin inflammation (Darier sign). | Investigations: Skin biopsy and haematological assessment in mastocytosis and hypereosinophilic syndrome. | **AR** = autosomal recessive; **AD** = autosomal dominant; **XLD** = X-linked dominant; **XLR** = X-linked recessive |

Table 1. *Diseases associated with erythroderma and useful diagnostic features.*
| Description of study | Differential causes | Demographics (Age and sex) | Reference |
|----------------------|---------------------|---------------------------|-----------|
| Case series 97 patients with acquired erythroderma in Iran | 59.7% Dermatoses  
21.6% Drug reactions  
11.3% Malignancies  
7.2% Idiopathic | Median age at diagnosis 46.2 years  
Male: Female ratio 1.85:1 | Akhyani et al, 2005<sup>20</sup> |
| Case series 49 patients with acquired erythroderma in Thailand | 38.77% Drugs  
27.5% Dermatoses | Median age at presentation 51.7 years  
Male: Female ratio 2:1 | Leenuta phong et al, 1999<sup>26</sup> |
| Case series of 309 patients in Brazil | 20.7% Eczema  
16.8% psoriasis  
12.3% Sezary syndrome  
12.3% Drug eruption  
8.7% Atopic dermatitis  
5.5% Mycosis fungoides  
6.8% Others  
16.8% Idiopathic | Median age 57 years  
Male: Female ratio 2.2 | Miyashiro and Sanches, 2020<sup>2</sup> |
| Case series of 25 patients in Porur, India | 32% Psoriasis | Age range of 5 days to 72 years. | Sudho et al, 2003<sup>27</sup> |
|---|---|---|---|
| | 24% Drugs | Peak incidence 21-30 years (24%) | |
| | 12% Eczema | Male: female ratio 1.5:1 | |
| | 8% Hereditary disorders | | |
| | 4% Pemphigus foliaceus | | |
| | 12% Others (including malignancy, Dermatophytosis, SSSS and Pityriasis rubra pilaris) | | |

| Case series of 370 patients in Kerala, India | 32.7% Psoriasis | Male: Female ratio of 3.6:1 | Mathew et al, 2017<sup>21</sup> |
|---|---|---|---|
| | 15.9% Contact dermatitis | | |
| | 15.7% Idiopathic | Mean age of onset of erythroderma was 55.38 ± 16.67 (range 3-91 years) years | |
| | 8.1% Chronic actinic dermatitis | | |
| | 6.5% Drugs | | |
| | 6.5% Atopic dermatitis | | |
| | 3.2% Malignancy | | |
| | 3.2% Pityriasis rubra pilaris | | |
| | 1.4% Pemphigus foliaceus | | |
| | 0.8% Other- including crusted scabies and congenital ichthyosiform erythroderma | | |

| Case series of | | | Yuan et al, 2014<sup>25</sup> |
|---|---|---|---|
| Study Description | Differential Causes | Gender Ratio | Mean Age |
|-------------------|---------------------|--------------|----------|
| 82 patients in China | 72% Pre-existing dermatoses (30.5% Psoriasis) 17% Drug Reactions 6.1% Idiopathic causes 4.9% malignancies | | |
| Retrospective study of 80 erythrodermic adults in Africa | 51.25% Psoriasis 11.25% Drugs 8.75% Malignancy 7.5% Idiopathic 6.25% Pemphigus foliaceus 2.5% Contact Dermatitis 1.25% Pityriasis rubra pilaris 1.25% Pemphigus foliaceus | Male: Female 2.2: 1.0 | Average age 53.78 +/- 18 years. |
| Case series of 90 patients in Pakistan | 37.8% Psoriasis 14.6% Idiopathic 7.8% Congenital ichthyosiform erythroderma 5.6% Pemphigus foliaceus 5.5% Drugs 5.5% Malignancy 3.3% Atopic dermatitis 3.3% Contact Dermatitis 2.2% Crusted Scabies 2.2% Pityriasis rubra pilaris | Male: Female ratio of 2.8: 1 | Mean age of onset 41.6 years |

Table 2. Literature review of the differential causes of erythroderma from different geographical locations worldwide.